COMMUNIQUÉS West-GlobeNewswire

BeiGene to Present Tislelizumab Data in Urothelial Carcinoma at the 2018 Genitourinary Cancers Symposium
05/02/2018
CAMBRIDGE, Mass. and BEIJING, China, Feb. 05, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE ), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly [...]
ImmuCell to Announce Financial Results for Fourth Quarter and Full Year 2017
05/02/2018
PORTLAND, Maine, Feb. 05, 2018 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC ) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and [...]
Results from Phase I Study of CB-839 in Combination with Everolimus or Cabozantinib in Patients with Renal Cell Carcinoma to be Presented at the 2018 American Society of Clinical Oncology Genitourinary Cancer Symposium
05/02/2018
-Overall response rate of 40% and 100% disease control rate in advanced clear cell renal cell carcinoma patients treated with CB-839 plus Cabozantinib -Randomized placebo controlled CANTATA Phase 2 trial of CB-839 in [...]
Mesa Labs Reports Third Quarter Results
05/02/2018
LAKEWOOD, Colo., Feb. 05, 2018 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ: MLAB ) (we, us, our, “Mesa” or the “Company”) today reported its results for the third quarter ended December 31, 2017. Revenues for [...]
Argos Obtains Option to License PD1 Checkpoint Inhibitors
05/02/2018
- Data showing synergy between PD1 checkpoint inhibition and analogue of Rocapuldencel-T in a preclinical model of renal carcinoma presented at ASCO-SITC - - Company to host a conference call on Tuesday, February 6, [...]
T2 Biosystems Announces CFO Transition
05/02/2018
LEXINGTON, Mass., Feb. 05, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO ) a leader in the development of innovative medical diagnostic products for critical unmet needs in healthcare, today announced that [...]
Actinium Pharmaceuticals to Present at the BIO CEO & Investor Conference
05/02/2018
NEW YORK, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company") announced today that it will be attending and presenting at the BIO CEO & Investor [...]
Quotient Limited Updates on Status of MosaiQ Performance and Provides Third Quarter Fiscal 2018 Financial Results
05/02/2018
Manufacturing process change implemented with improved assay performance Verification and Validation (V&V) studies for blood grouping to resume MosaiQ SDS Microarray preparing to enter into formal V&V studies [...]
Ossur Hf : Interim Report Q4 2017 and Annual Report 2017
05/02/2018
Announcement no. 8/2018 5 February 2018 Highlights Sales in Q4 2017 amounted to USD 154 million, corresponding to 7% organic growth. Sales for FY 2017 amounted to USD 569 million, corresponding to 8% growth and 5% [...]
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
05/02/2018
MALVERN, Pa., Feb. 05, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS ), a dermatologist-led, biopharmaceutical company focused on identifying, developing and commercializing innovative and [...]
Nuvectra™ Announces Closing of Follow-On Stock Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
05/02/2018
PLANO, Texas, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR ), a neurostimulation medical device company, announced today the closing of its underwritten follow-on public offering of 3,248,750 [...]
Bio-Path Holdings to Present at the BIO CEO & Investor Conference
05/02/2018
HOUSTON, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH ), a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of [...]
Sol-Gel Technologies Ltd. Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
05/02/2018
NESS ZIONA, Israel, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (“Sol-Gel”) (NASDAQ: SLGL ), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and [...]
Emblem Announces Changes to Board of Directors
05/02/2018
TORONTO, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Emblem Corp. (TSXV:EMC) (EMC.WT) (" Emblem " or the " Corporation ") announces that Mr. Gordon Fox, a director and founder of the Corporation, has tendered his resignation from [...]
GW Pharmaceuticals Announces the European Medicines Agency (EMA) Accepts Epidiolex® (cannabidiol) Marketing Authorization Application (MAA) for Review
05/02/2018
LONDON and CARLSBAD, Calif., Feb. 05, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH ) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and [...]
GW Pharmaceuticals plc Reports Fiscal First Quarter 2018 Financial Results and Operational Progress
05/02/2018
- Epidiolex ® (cannabidiol) NDA and MAA applications accepted for review – - NDA PDUFA goal date scheduled for June 27, 2018 - - Conference call today at 4:30 p.m. EST - LONDON and CARLSBAD, Calif., Feb. 05, 2018 (GLOBE [...]
Novo Nordisk A/S - Share repurchase programme
05/02/2018
Bagsværd, Denmark, 5 February 2018 - As part of the up to DKK 14 billion 2018 share repurchase programme, Novo Nordisk A/S has now initiated a new share repurchase programme for an amount of up to DKK 2.5 billion in [...]
BLVD Centers Announces Date and Time for End Of Quarter Update Conference Call
05/02/2018
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES LOS ANGELES, Feb. 05, 2018 (GLOBE NEWSWIRE) -- BLVD Centers Corporation (TSXV:CXV), a leading company in the United [...]
Novo Nordisk A/S purchases B shares worth DKK 954 million from Novo Holdings A/S under the 2018 share repurchase programme
05/02/2018
Bagsværd, Denmark, 5 February 2018 - Novo Nordisk A/S has today entered into an agreement to purchase 3,087,410 B shares (nominal DKK 0.20) of a value of DKK 954 million from Novo Holdings A/S. This transaction is part [...]

Pages